Print Page     Close Window     
MESOBLAST LTD filed this Form 6-K on 08/31/2018
Entire Document

Slide 27

MPC-06-ID: Phase 3 trial in patients with chronic low back pain | Phase 3 study completed enrollment in March 2018 Over 400 patients were enrolled at 48 sites across the US and Australia Patients randomized 1:1:1 to receive saline, 6-million MPCs with hyaluronic acid and 6-million MPCs without hyaluronic acid Primary efficacy composite endpoint requires a patient to achieve: Reduction in pain (50% decrease in Visual Analog Score) and improvement in function (15 point improvement in as measured by the Oswestry Disability Index) No additional intervention at the treated level through 24 months Primary endpoint at 12 and 24 months  

Copyright © 2015 Mesoblast Inc.